digoxin has been researched along with Thyroid-Neoplasms* in 1 studies
1 other study(ies) available for digoxin and Thyroid-Neoplasms
| Article | Year |
|---|---|
Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Non-medullary thyroid cancer (NMTC) treatment is based on the ability of thyroid follicular cells to accumulate radioactive iodide (RAI). However, in a subset of NMTC patients tumor dedifferentiation occurs, leading to RAI resistance. Digoxin has been demonstrated to restore iodide uptake capacity in vitro in poorly differentiated and anaplastic NMTC cells, termed redifferentiation. The aim of the present study was to investigate the in vivo effects of digoxin in TPO-Cre/LSL-Braf. We found that in mice, tumor growth was inhibited and. These in vivo data support the hypothesis that digoxin may represent a repositioned adjunctive treatment modality that suppresses tumor growth and improves RAI sensitivity in patients with RAI-refractory NMTC. Topics: Aged; Aged, 80 and over; Animals; Autophagy; Cell Proliferation; Digoxin; Female; Humans; Iodine Radioisotopes; Male; Mice; Radiation Tolerance; Radiation-Sensitizing Agents; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2021 |